Therapeutics News and Research

RSS

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Agile Therapeutics announced results today from a Phase 2 clinical study of AG200-15, Agile's weekly contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). According to the clinical findings, AG200-15 provides a low daily dose of estrogen equivalent to 30 micrograms EE, similar to that in low-dose, oral contraceptive (OC) pills.

26 Oct 2010

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Compugen Ltd. today reported financial results for the third quarter ending September 30, 2010.

26 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

aTyr Pharma announces $23 million Series C equity financing

aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates. Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing.

26 Oct 2010

Omeros to develop new drugs for major diseases

The Life Sciences Discovery Fund (LSDF) today announced a $5 million grant to Seattle-based Omeros Corporation (NASDAQ: OMER) to discover, develop, and commercialize new drugs to treat a variety of major diseases. With successful generation of proceeds through partnering and the sales of drugs in the marketplace, an additional outcome of the grant would be establishment of a new non-profit initiative to advance the life sciences sector and improve health and economic growth in Washington state.

26 Oct 2010

Innovative program for new graduate doctors to ensure safety prescription

A new software based program has recently been created for new graduate doctors to ensure they prescribe safely from day one on the wards.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

Trius receives patent protection for torezolid phosphate in the U.S.

Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).

26 Oct 2010

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

26 Oct 2010

Baxter announces launch of GLASSIA in the U.S.

Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.

From Baxter International Inc. 26 Oct 2010

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies "Biosimilars" for the Treatment of Cancer.

26 Oct 2010

Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone

Repros Therapeutics Inc. today announced it has commenced randomization of subjects into its Phase II Androxal® study in the treatment of type 2 diabetes (T2DM) in men with low testosterone. Low testosterone and T2DM are co-morbid conditions in a significant number of men. The study is being conducted at nine sites across the US including both academic and private practices and will enroll up to 150 patients.

25 Oct 2010

New gene therapy product reduces plasma cholesterol levels

Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans

25 Oct 2010

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, will present promising clinical data for CMX001 in a late-breaker poster session at the Infectious Diseases Society of America (IDSA) 48th Annual Meeting.

25 Oct 2010

UCLA researchers receive grant to develop medical products against radiation exposure

Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.

25 Oct 2010

Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting

Revance Therapeutics, Inc. today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinum toxin type A which is under investigation for the treatment of lateral canthal lines (crow's feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago.

25 Oct 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the "6th Annual Meeting of the Oligonucleotide Therapeutics Society" held October 20 - 23, 2010 in Dana Point, California.

22 Oct 2010

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

Therapeutics News and Research

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

aTyr Pharma announces $23 million Series C equity financing

Omeros to develop new drugs for major diseases

Innovative program for new graduate doctors to ensure safety prescription

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Trius receives patent protection for torezolid phosphate in the U.S.

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

Baxter announces launch of GLASSIA in the U.S.

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone

New gene therapy product reduces plasma cholesterol levels

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

UCLA researchers receive grant to develop medical products against radiation exposure

Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Dicerna secures $4 million in second closing of Series B equity financing

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News